Skip to the page

Data / Drug companies / Cranbury Pharmaceuticals, LLC

Cranbury Pharmaceuticals, LLC: 72 products in the FDA NDC directory, labeler code 27808

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Cranbury Pharmaceuticals, LLC (labeler code 27808) lists 72 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 72 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 1, 2026.

The request: Watch Cranbury Pharmaceuticals, LLC (FDA labeler code 27808): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
27808
Products in commercial distribution
72
Packages
106
Finished drugs by generic name
30
Prescription products
72
Over the counter products
0
Controlled substance products
Schedule II 18, Schedule IV 1, Schedule V 12
Flagged as original packager
59 of 59 products that carry the flag
Started marketing in the last 12 months
9
Products with a marketing end date set
3
Earliest marketing start
November 30, 2001
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)72100%

Products by type

TypeProductsShare
Prescription drugs72100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet2433.3%
Solution1216.7%
Capsule1115.3%
Tablet, extended release811.1%
Capsule, extended release811.1%
Tablet, film coated56.9%
Syrup22.8%
Suspension, extended release11.4%
Suspension11.4%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Topiramate27808-329Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Topiramate27808-328Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Topiramate27808-327Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Topiramate27808-326Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Topiramate27808-325Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Diltiazem Hydrochloride27808-324Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Diltiazem Hydrochloride27808-323Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Diltiazem Hydrochloride27808-322Capsule, extended releaseGeneric drugs (ANDA)October 1, 2026
Cabergoline27808-315TabletGeneric drugs (ANDA)August 1, 2026
Metoprolol Succinate27808-305Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Metoprolol Succinate27808-304Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Metoprolol Succinate27808-303Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Metoprolol Succinate27808-302Tablet, extended releaseGeneric drugs (ANDA)June 1, 2025
Tramadol hydrochloride27808-301Tablet, film coatedGeneric drugs (ANDA)December 22, 2024
Celecoxib27808-297CapsuleGeneric drugs (ANDA)December 1, 2024
Celecoxib27808-296CapsuleGeneric drugs (ANDA)December 1, 2024
Celecoxib27808-295CapsuleGeneric drugs (ANDA)December 1, 2024
Deflazacort Oral Suspension27808-249SuspensionGeneric drugs (ANDA)May 1, 2024
Levetiracetam27808-266TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam27808-265TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam27808-264TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam27808-263TabletGeneric drugs (ANDA)May 1, 2023
Dextroamphetamine Sulfate27808-090TabletGeneric drugs (ANDA)August 20, 2022
Dextroamphetamine Sulfate27808-089TabletGeneric drugs (ANDA)August 20, 2022
Lacosamide27808-246TabletGeneric drugs (ANDA)March 19, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.